Prognostic Impact of Myosteatosis in Patients with Gastric Cancers：A Systematic Review and Meta-Analysis

Abstract

Review question / Objective: Myosteatosis may a better predictor than sarcopenia. Clinicians should strengthen the screening of myosteatosis in patients of GC and give active l support to improve the prognosis of patients. Eligibility criteria: We assigned two authors independently to search for relevant studies and screen the literature using titles and abstracts. After the initial screening, the full text of the articles that satisfied the inclusion criteria were evaluated. In this study, we established following inclusion criteria: 1) adults diagnosed with GC. 2) The primary outcome for these studies include overall survival (OS) or/and disease free survival (DFS) with myosteatosis or radiodensity as one of the variables. 3) The decrease of HU was used as the diagnostic criterion for myosteatosis. The exclusion criteria were as follows: 1) case reports, reviews, conference abstracts or preclinical studies, 2) studies citing literature with incomplete data, and 3) nonhuman studies. If the same patient cohort was used in multiple studies, the latest and more complete data were adopted in this meta-analysis. INPLASY registration number:This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 07 June 2023 and was last u p d a t e d o n 0 7 J u n e 2 0 2 3 ( r e g i s t r a t i o n n u m b e r INPLASY202360024).